Accès gratuit
Numéro
Med Sci (Paris)
Volume 19, Numéro 11, Novembre 2003
Page(s) 1052 - 1054
Section Le Magazine : Nouvelles
DOI https://doi.org/10.1051/medsci/200319111052
Publié en ligne 15 novembre 2003
  1. Baselga J, Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep 2002; 4: 317–24. [Google Scholar]
  2. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMCC225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a (abstract 7). [Google Scholar]
  3. Kim ES, Mauer AM, Fossella FV, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 293a (abstract 1168). [Google Scholar]
  4. Garcia de Palazzo IE, Adams GP, Sunderaresham P, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993; 53: 3217–20. [Google Scholar]
  5. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine-kinase inhibitor. Clin Cancer Res 2000; 6: 2053–63. [Google Scholar]
  6. Naruse I, Ohmori T, Ao Y, et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 2002; 98: 310–5. [Google Scholar]
  7. Helfrich B, Phistry M, Chan D, et al. ZD1839 (Iressa), a selective EGFR-TKI enhances radiation and chemotherapy cytotoxicity in EGFR positive human non-small cell lung cancer cells (NSCLC) in vitro. Am Ass Cancer Res 2001; 2: 12–6. [Google Scholar]
  8. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237–46. [Google Scholar]
  9. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL2). Proc Am Soc Clin Oncol 2002; 21: 292a (abstract 1166). [Google Scholar]
  10. Giaccone G, Johnson D, Manegold C, et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT1). Ann Oncol 2002; 13: 2 (abstract4). [Google Scholar]
  11. Johnson D, Herbst R, Giaccone G, et al. ZD1839(Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced nonsmall cell lung cancer(NSCLC): results from a phase III trial (INTACT2). Ann Oncol 2002; 13: 127 (abstract 468). [Google Scholar]
  12. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361: 137–9. [Google Scholar]
  13. Gupta N, Ahmed I, Steinberg H, et al. Gemcitabineinduced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 2002; 25: 96–100. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.